In psoriasis, TKIs targeting pathways like VEGFR and EGFR could be combined with IL‐23 or IL‐17 inhibitors to address not only inflammation but also pathological keratinocyte proliferation and angiogenesis. Here, IL17A is linked to psoriasis.